The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 8.676 on June 20, 2019. JITC’s impact factor places JITC in the top 3 percent of all fully open access oncology journals and ranks it in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2018 citations accumulated for JITC manuscripts published in 2016 and 2017. Other journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 60 percent discount on processing fees for all JITC articles submitted and accepted in 2019. To take advantage of this SITC member benefit, authors must contact JITC Managing Editor Andrea Kunz at JITCEditor@sitcancer.org or (414) 271-2456 prior to submission to obtain a discount code and instructions.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation in primary rather than metastatic sites, and in biopsy samples, which may not be representative. These limitations may be overcome with immuno–positron emission tomography (iPET), an emerging tool allowing the detection of cell surface proteins with radiolabeled antibodies. Here, we report iPET studies of PD-L1 in a preclinical tumorgraft model of clear cell RCC (ccRCC) from a patient who had a favorable response to anti-PD-1 therapy.
Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have taken the approach of comprehensive screening all neoantigen candidates, with a validation rate of 0.5–2%.
2019 Annual Cancer Treatment-Related Adverse Events Symposium
Friday-Saturday, October 25-26, 2019 Memorial Sloan Kettering Cancer Center Register online: http://www.mskcc.org/AdverseEvents
Systemic anticancer therapies (cytotoxic ...
I would like to personally invite you to join Kim Margolin, MD, Ahmad Tahini, MD, PhD, and myself for SITC Webinar: I-O Highlights from ASCO 2019 , a free SITC webinar on Aug. 28 at Noon EDT where we discuss the latest advances ...
Multiplex Immunofluorescence in Immune Oncology
Four Day Symposium and Workshop program divided into a lectures series given by world class scientists specializing ...
For those of you in the Philadelphia area, CAR-T and The Rise of the Cellicon Valley Thursday, May 9 and Friday, May 10, 2019 World experts in CAR T-cellular therapy and hematopoietic stem cell transplantation (HSCT) have been assembled to ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org